3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Turcot syndrome
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Ascites
1
Interventions
Cisplatin
139
pembrolizumab
88
Carboplatin
73
Radiotherapy
71
Cetuximab
69
Docetaxel
58
Paclitaxel
52
Radiotherapy, Intensity-Modulated
43
Fluorouracil
43
Nivolumab
32
Surgical Procedures, Operative
18
Albumin-Bound Paclitaxel
15
130-nm albumin-bound paclitaxel
15
Radiation
14
Drug Therapy
14
tislelizumab
13
Taxes
13
durvalumab
12
Magnetic Resonance Spectroscopy
12
toripalimab
11
camrelizumab
11
Platinum
11
Chemoradiotherapy
11
Biopsy
11
cemiplimab
10
Radiosurgery
10
Erlotinib Hydrochloride
10
Capecitabine
10
Specimen Handling
9
Neoadjuvant Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Squamous Cell Carcinoma of Head and Neck
×
danvatirsen
×
Clear all
NCT05814666
2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2
Terminated
69 enrolled
21 charts